ATYR aTyr Pharma, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 7, 2026ATYR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ATYR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| July 1, 2019 | 1-for-14 | Reverse |
About aTyr Pharma, Inc. - Common Stock Company overview from Wikipedia
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
History
In 2005, aTyr was founded by Paul Schimmel, and Xiang-Lei Yang, two aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In 2009, Bruce Beutler, recipient of the 2011 Nobel Prize in Physiology or Medicine, joined aTyr as a member of the scientific advisory board.
In April 2007, Polaris Partners and Alta Partners co-led a $10.5 million Series B financing. In October 2010, Series C financing totaled $23 million and was led by Domain Associates. This round was followed by a $49 million Series D in August 2013.
aTyr was a winner of the 2011 Red Herring 100 North America Award for discovering and developing innovative medicines based on Physiocrine biology.
In April 2015, aTyr raised $76 million in a Series E, led by Sofinnova Ventures, and filed for an IPO. The company began trading as LIFE on the Nasdaq stock exchange.
ATyr's primary focus is on ATYR1923, a clinical stage product candidate which binds to the NRP2 receptor and is designed to down regulate immune engagement in interstitial lung diseases (ILDs). ATYR1923 is currently being investigated in a clinical trial in patients with pulmonary sarcoidosis. In January 2020, ATyr entered into a license with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. Under the license agreement, Kyorin received an exclusive right to develop and commercialize ATYR1923 in Japan for all forms of ILDs including, sarcoidosis, chronic hypersensitivity pneumonitis (CHP) and connective tissue disease ILD (CTD-ILD). aTyr recently initiated a clinical trial for ATYR1923 in patients with severe respiratory complications related to COVID-19.
Therapeutic concept
Homeostasis, or the coordinated regulation of tissues within the body, is fundamental to the maintenance of the overall health of an organism. Lack of homeostasis can lead to disease and death. The process of homeostasis was first described in 1865 by the French physiologist Claude Bernard and Walter Cannon later coined the term. In the 150 years since this discovery, many proteins associated with homeostatic pathways have been discovered, ranging from insulin to erythropoietin.
aTyr was founded after Dr. Schimmel discovered several nontranslational functions of aminoacyl tRNA synthetases, which are primarily responsible for the production of a vital component of protein synthesis, aminoacyl-tRNAs. [23] These nontranslational functions have since been shown to play an important role in maintaining homeostasis. [23] One of these nontranslational functions is modulation and regulation of the immune response. [23] This modulatory activity is a result of Physiocrines, a novel class of proteins that are present as biologically active signaling regions of the tRNA synthetases. aTyr's research is based on the premise that Physiocrines are involved in orchestrating homeostatic activities to help the body restore diseased or damaged tissue to a healthier state.
By researching and understanding the role of Physiocrines in immune modulation, aTyr has developed two IND candidates.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ATYR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.45Y avg ≈-2.5 | ≈-2.5 | · | · | |
| P/S | 148.25Y avg ≈489.4 | ≈489.4 | 60.5 | Overvalued | |
| P/B (MRQ) | 0.65Y avg ≈1.9 | ≈1.9 | · | · | |
| Price / FCF (TTM) | -0.55Y avg ≈-3.1 | ≈-3.1 | · | · | |
| Price / Cash Flow (TTM) | -0.55Y avg ≈-3.2 | ≈-3.2 | · | · | |
| Price / Tangible Book | 0.45Y avg ≈1.9 | ≈1.9 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ATYR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin | -40856.3%5Y avg ≈-21440.1% | ≈-21440.1% | -1518.6% | Weak | |
| EBITDA Margin | -40506.8%5Y avg ≈-21234.9% | ≈-21234.9% | -1473.1% | Weak | |
| Pretax Margin | -39012.1%5Y avg ≈-20242.1% | ≈-20242.1% | · | · | |
| Net Profit Margin | -39009.5%5Y avg ≈-20241.1% | ≈-20241.1% | -178.5% | Weak | |
| ROA | -78.1%5Y avg ≈-54.0% | ≈-54.0% | -66.7% | Below avg | |
| ROE | -107.8%5Y avg ≈-69.5% | ≈-69.5% | -46.5% | Below avg | |
| ROIC | -115.0%5Y avg ≈-73.7% | ≈-73.7% | -60.4% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ATYR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 5.15Y avg ≈8.4 | ≈8.4 | 2.0 | Strong liquidity | |
| Quick Ratio | 0.75Y avg ≈0.8 | ≈0.8 | 1.1 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ATYR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -19.1%5Y avg ≈-49.7% | ≈-49.7% | · | · | |
| Revenue CAGR 3Y | -73.7% | · | · | · | |
| Revenue CAGR 5Y | -55.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ATYR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.0 | ≈0.0 | 0.0 | Weak | |
| Revenue / Employee | ≈$3.3K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $-0.11 | $-0.12 | 11.2% |
| March 31, 2026 | May 15, 2026 | $-0.11 | $-0.14 | 21.6% |
| Dec. 31, 2025 | $-0.14 | $-0.19 | 25.3% | |
| Sept. 30, 2025 | $-0.26 | $-0.19 | -38.8% | |
| June 30, 2025 | $-0.22 | $-0.19 | -17.0% | |
| March 31, 2025 | $-0.17 | $-0.19 | 12.3% | |
| Dec. 31, 2024 | $-0.18 | $-0.23 | 21.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| R&D Expense | $60M | $54M | $42M | $43M | $23M | $17M | $14M | |
| SG&A Expense | $18M | $14M | $13M | $14M | $11M | $9M | $9M | |
| Operating Expenses | $78M | $68M | $55M | $57M | $34M | $26M | $23M | |
| Operating Income | $-78M | $-68M | $-55M | $-46M | $-34M | $-16M | $-23M | |
| Other Non-op | $4M | $4M | $5M | $1M | $238.0K | $-319.0K | $-785.0K | |
| Pretax Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-24M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| EPS (Basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| EPS (Diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| Shares (Basic) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| Shares (Diluted) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| EBITDA | $-77M | $-67M | $-54M | $-46M | $-34M | $-15M | $-22M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $11M | $23M | $10M | $2M | $17M | $9M | |
| Prepaid Expense | $677.0K | $8M | $2M | $3M | $5M | $2M | $681.0K | |
| Current Assets | $80M | $82M | $103M | $81M | $114M | $36M | $32M | |
| PP&E (Net) | $4M | $5M | $6M | $3M | $543.0K | $899.0K | $1M | |
| PP&E (Gross) | $9M | $9M | $10M | $9M | $7M | $8M | $7M | |
| Accum. Depreciation | $5M | $5M | $5M | $6M | $6M | $7M | $6M | |
| Other Non-current Assets | $148.0K | $66.0K | $131.0K | $193.0K | $158.0K | $213.0K | $172.0K | |
| Total Assets | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Accounts Payable | $4M | $4M | $4M | $3M | $1M | $1M | $847.0K | |
| Accrued Liabilities | $10M | $9M | $12M | $10M | $4M | $4M | $2M | |
| Current Liabilities | $15M | $15M | $16M | $14M | $6M | $6M | $13M | |
| Capital Leases | $10M | $11M | $12M | $10M | $398.0K | $1M | $2M | |
| Total Debt | · | · | · | · | · | · | $9M | |
| Common Stock | $98.0K | $84.0K | $63.0K | $29.0K | $28.0K | $11.0K | $4.0K | |
| Paid-in Capital | $674M | $602M | $559M | $490M | $482M | $370M | $344M | |
| Retained Earnings | $-606M | $-532M | $-468M | $-418M | $-372M | $-339M | $-322M | |
| AOCI | $-8.0K | $-40.0K | $-74.0K | $-433.0K | $-263.0K | $-43.0K | $-40.0K | |
| Stockholders' Equity | $67M | $70M | $91M | $71M | $109M | $32M | $21M | |
| Liabilities + Equity | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Shares Outstanding | 98,031,014 | 84,038,922 | 63,286,404 | 29,498,488 | 27,793,035 | 11,018,954 | 3,891,787 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K | $569.0K | $635.0K | |
| Other Non-cash | $11M | $-6M | $17M | $3M | $218.0K | $354.0K | $3M | |
| Operating Cash Flow | $-62M | $-69M | $-33M | $-42M | $-33M | $-15M | $-20M | |
| CapEx | $77.0K | $65.0K | $4M | $2M | $192.0K | $202.0K | $79.0K | |
| Investing Cash Flow | $-5M | $17M | $-20M | $47M | $-92M | $7M | $5M | |
| Financing Cash Flow | $66M | $40M | $66M | $5M | $110M | $16M | $1M | |
| Net Change in Cash | $-1M | $-12M | $13M | $11M | $-15M | $8M | $-14M | |
| Free Cash Flow | $-62M | $-69M | $-37M | $-44M | $-33M | $-16M | $-20M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | · | -152.2% | -5445.0% | |
| Net Margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | · | -155.2% | -5593.1% | |
| Pretax Margin | -39012.1% | -27243.4% | -14276.2% | -436.6% | · | -155.2% | -5631.0% | |
| EBITDA Margin | -40506.8% | -28598.3% | -15390.1% | -444.6% | · | -146.7% | -5294.6% | |
| ROA | -78.1% | -58.9% | -46.6% | -42.9% | -43.8% | -43.3% | -53.1% | |
| ROE | -107.8% | -79.7% | -62.2% | -50.2% | -47.9% | -61.4% | -98.5% | |
| ROIC | -115.0% | -97.0% | -60.6% | -64.9% | -31.1% | -50.3% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 | 6.1 | 2.5 | |
| Quick Ratio | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 | 2.9 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | 0.4 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.1 | · | 0.3 | 0.0 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.69 | $0.83 | $1.43 | $2.42 | $3.93 | $2.87 | $5.44 | |
| Revenue / Share | $0.00 | $0.00 | $0.01 | $0.37 | · | · | · | |
| Cash Flow / Share | $-0.67 | $-0.93 | $-0.62 | $-1.47 | · | · | · | |
| Cash / Share | $0.11 | $0.13 | $0.36 | $0.34 | $0.08 | $1.54 | $2.37 | |
| EPS (TTM) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -19.1% | -33.4% | -96.6% | · | · | · | · | |
| Revenue CAGR 3Y | -73.7% | · | -67.7% | · | · | · | · | |
| Revenue CAGR 5Y | -55.1% | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| Net Income TTM | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| Market Cap | $77M | $304M | $89M | $65M | $208M | $43M | $16M | |
| Enterprise Value | · | · | · | · | · | · | $16M | |
| P/E | -1.0 | -4.2 | -1.5 | -1.4 | -4.2 | -2.2 | · | |
| P/S | 404.0 | 1294.6 | 252.8 | 6.2 | · | 4.1 | 38.5 | |
| P/B | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | 0.8 | |
| P / Tangible Book | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | · | |
| P / Cash Flow | -1.2 | -4.4 | -2.7 | -1.5 | -6.3 | -2.8 | -0.8 | |
| P / FCF | -1.2 | -4.4 | -2.4 | -1.5 | -6.2 | -2.8 | -0.8 | |
| EV / EBITDA | · | · | · | · | · | · | -0.7 | |
| EV / FCF | · | · | · | · | · | · | -0.8 | |
| EV / Revenue | · | · | · | · | · | · | 37.3 | |
| Earnings Yield | -102.2% | -23.8% | -66.7% | -73.1% | -23.7% | -45.6% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $190.0K | $0 | $0 | $0 | $0 | $0 | $235.0K | $353.0K | $0 | $0 | $0 | · | · | |
| R&D Expense | $7M | $7M | $11M | $22M | $15M | $12M | $12M | $15M | $14M | $13M | $10M | $10M | $9M | $10M | $9M | $9M | |
| SG&A Expense | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | |
| Operating Expenses | $11M | $11M | $15M | $27M | $20M | $16M | $16M | $18M | $17M | $17M | $13M | $14M | $13M | $13M | $13M | $12M | |
| Operating Income | $-11M | $-11M | $-15M | $-27M | $-20M | $-16M | $-16M | $-18M | $-17M | $-17M | $-13M | $-14M | $-13M | $-13M | $-13M | $-12M | |
| Other Non-op | $571.0K | $644.0K | $832.0K | $999.0K | $781.0K | $892.0K | $852.0K | $882.0K | $1M | $1M | $1M | $1M | $835.0K | $247.0K | $163.0K | $224.0K | |
| Net Income | $-10M | $-11M | $-14M | $-26M | $-20M | $-15M | $-15M | $-17M | $-16M | $-15M | $-11M | $-12M | $-12M | $-13M | $-12M | $-12M | |
| EPS (Basic) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.46 | $-0.44 | $-0.44 | |
| EPS (Diluted) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.46 | $-0.44 | $-0.44 | |
| Shares (Basic) | 98,069,915 | 98,043,839 | · | 97,153,541 | 90,120,235 | 86,485,126 | · | 75,801,666 | 72,284,351 | 66,080,593 | 57,885,393 | 55,143,805 | 41,897,706 | 28,663,047 | 28,063,387 | 27,818,379 | |
| Shares (Diluted) | 98,069,915 | 98,043,839 | · | 97,153,541 | 90,120,235 | 86,485,126 | · | 75,801,666 | 72,284,351 | 66,080,593 | 57,885,393 | 55,143,805 | 41,897,706 | 28,663,047 | 28,063,387 | 27,818,379 | |
| EBITDA | $-11M | $-11M | · | $-27M | $-20M | $-16M | · | $-18M | $-17M | $-16M | $-13M | $-14M | $-13M | $-13M | $-13M | $-12M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $10M | $11M | $6M | $17M | $10M | $11M | $11M | $7M | $7M | $10M | $12M | $21M | $18M | $8M | $8M | |
| Short-term Investments | · | · | · | $79M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $518.0K | $586.0K | $677.0K | $2M | $7M | $6M | $8M | $8M | $10M | $10M | $3M | $5M | $3M | $6M | $4M | $4M | |
| Current Assets | $58M | $68M | $80M | $93M | $87M | $83M | $82M | $76M | $90M | $97M | $107M | $114M | $119M | $85M | $93M | $103M | |
| PP&E (Net) | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $5M | $1M | $558.0K | $433.0K | |
| PP&E (Gross) | · | · | $9M | · | · | · | $9M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $190.0K | $148.0K | $148.0K | $149.0K | $66.0K | $66.0K | $66.0K | $130.0K | $130.0K | $130.0K | $73.0K | $72.0K | $144.0K | $169.0K | $175.0K | $176.0K | |
| Total Assets | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | $125M | $133M | $137M | $96M | $96M | $105M | |
| Accounts Payable | $3M | $3M | $4M | $4M | $4M | $2M | $4M | $4M | $1M | $5M | $2M | $516.0K | $4M | $3M | $2M | $2M | |
| Accrued Liabilities | $7M | $7M | $10M | $10M | $10M | $8M | $9M | $9M | $9M | $10M | $10M | $11M | $9M | $7M | $7M | $4M | |
| Current Liabilities | $11M | $12M | $15M | $16M | $16M | $11M | $15M | $14M | $12M | $16M | $13M | $12M | $14M | $11M | $9M | $6M | |
| Capital Leases | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $13M | $12M | $7M | · | $133.0K | |
| Common Stock | $98.0K | $98.0K | $98.0K | $98.0K | $93.0K | $89.0K | $84.0K | $76.0K | $76.0K | $68.0K | $59.0K | $57.0K | $53.0K | $29.0K | $28.0K | $28.0K | |
| Paid-in Capital | $676M | $675M | $674M | $672M | $641M | $622M | $602M | $582M | $582M | $568M | $552M | $548M | $540M | $488M | $484M | $484M | |
| Retained Earnings | $-627M | $-617M | $-606M | $-592M | $-566M | $-547M | $-532M | $-517M | $-500M | $-484M | $-453M | $-442M | $-430M | $-410M | $-397M | $-384M | |
| AOCI | $-68.0K | $-70.0K | $-8.0K | $-1.0K | $-75.0K | $-66.0K | $-40.0K | $36.0K | $-168.0K | $-158.0K | $-294.0K | $-333.0K | $-248.0K | $-669.0K | $-810.0K | $-759.0K | |
| Stockholders' Equity | $49M | $58M | $67M | $80M | $75M | $75M | $70M | $65M | $82M | $84M | $98M | $106M | $110M | $77M | $87M | $99M | |
| Liabilities + Equity | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | $125M | $133M | $137M | $96M | $96M | $105M | |
| Shares Outstanding | 98,087,425 | 98,051,212 | 98,031,104 | 97,986,634 | 92,871,182 | 89,002,825 | 84,038,922 | 75,811,286 | 75,796,198 | 68,354,033 | 58,560,061 | 57,046,172 | 53,339,611 | 29,009,382 | 28,127,458 | 28,056,249 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $168.0K | $162.0K | $166.0K | $165.0K | $166.0K | $167.0K | $175.0K | $178.0K | $177.0K | $178.0K | $176.0K | $161.0K | $80.0K | $49.0K | $63.0K | $81.0K | |
| Other Non-cash | · | $-2M | · | · | · | $-707.0K | · | · | · | $-7M | · | · | $11M | · | · | $2M | |
| Operating Cash Flow | $-9M | $-13M | $-12M | $-20M | $-14M | $-15M | $-13M | $-13M | $-20M | $-22M | $-10M | $-12M | $-590.0K | $-12M | $-9M | $-10M | |
| CapEx | $73.0K | $138.0K | $31.0K | $37.0K | $9.0K | $0 | $25.0K | $15.0K | $8.0K | $17.0K | $557.0K | $2M | $1M | $426.0K | $53.0K | $43.0K | |
| Investing Cash Flow | $15M | $11M | $16M | $-20M | $3M | $-4M | $-6M | $18M | $7M | $-1M | $4M | $-4M | $-38M | $21M | $10M | $15M | |
| Financing Cash Flow | $-129.0K | $-142.0K | $-131.0K | $30M | $18M | $19M | $19M | $-105.0K | $13M | $8M | $3M | $8M | $49M | $3M | $39.0K | $1M | |
| Net Change in Cash | $6M | $-1M | $4M | $-11M | $7M | $-1M | $-378.0K | $5M | $-321.0K | $-16M | $-2M | $-8M | $11M | $11M | $893.0K | $6M | |
| Free Cash Flow | · | $-13M | · | · | · | $-15M | · | · | · | $-22M | · | · | $-2M | · | · | $-10M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -14076.3% | · | · | · | · | · | -7079.1% | -3573.7% | · | · | · | · | · | |
| Net Margin | · | · | · | -13549.5% | · | · | · | · | · | -6591.9% | -3212.5% | · | · | · | · | · | |
| EBITDA Margin | · | · | · | -14076.3% | · | · | · | · | · | -7003.4% | -3573.7% | · | · | · | · | · | |
| ROA | -12.0% | -12.2% | · | -26.0% | -18.8% | -14.1% | · | -15.9% | -13.7% | -12.4% | -10.3% | -10.8% | -9.9% | -12.0% | -17.1% | -15.2% | |
| ROE | -16.7% | -16.2% | · | -35.4% | -25.0% | -18.7% | · | -21.1% | -17.4% | -15.9% | -12.9% | -12.8% | -11.5% | -13.6% | -19.5% | -16.4% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 5.8 | · | 5.9 | 5.6 | 7.8 | · | 5.4 | 7.6 | 6.1 | 8.3 | 9.3 | 8.7 | 7.5 | 10.1 | 16.4 | |
| Quick Ratio | 1.4 | 0.9 | · | 5.4 | 1.1 | 1.0 | · | 0.8 | 0.6 | 0.4 | 0.8 | 1.0 | 1.5 | 1.6 | 0.9 | 1.3 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.50 | $0.59 | · | $0.82 | $0.81 | $0.84 | · | $0.86 | $1.08 | $1.24 | $1.68 | $1.86 | $2.06 | $2.66 | $3.08 | $3.51 | |
| Revenue / Share | · | · | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | $0.01 | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.13 | · | · | · | $-0.18 | · | · | · | $-0.34 | · | · | $-0.01 | · | · | · | |
| Cash / Share | $0.16 | $0.10 | · | $0.06 | $0.19 | $0.12 | · | $0.15 | $0.09 | $0.10 | $0.17 | $0.22 | $0.39 | $0.63 | $0.30 | $0.30 | |
| EPS (TTM) | $-0.63 | $-0.74 | · | $-0.82 | $-0.79 | $-0.80 | · | $-0.92 | $-0.89 | $-0.88 | $-0.97 | $-1.23 | $-1.45 | $-1.54 | $-1.50 | $-1.70 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $190.0K | · | $190.0K | $0 | $0 | · | $235.0K | $588.0K | $588.0K | $11M | $10M | · | · | $10M | $10M | |
| Net Income TTM | $-61M | $-70M | · | $-75M | $-67M | $-63M | · | $-64M | $-58M | $-54M | $-43M | $-45M | $-45M | $-46M | $-41M | $-39M | |
| Market Cap | $59M | $76M | · | $71M | $471M | $269M | · | $133M | $118M | $133M | $93M | $123M | $112M | $87M | $80M | $150M | |
| P/E | -0.9 | -1.1 | · | -0.9 | -6.4 | -3.8 | · | -1.9 | -1.8 | -2.2 | -1.6 | -1.8 | -1.4 | -1.9 | -1.9 | -3.1 | |
| P/S | 308.2 | 402.5 | · | 371.8 | · | · | · | 567.8 | 201.1 | 226.7 | 8.6 | 11.9 | · | · | 7.6 | 14.4 | |
| P/B | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | 0.9 | 1.2 | 1.0 | 1.1 | 0.9 | 1.5 | |
| P / Tangible Book | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | 0.9 | 1.2 | 1.0 | 1.1 | 0.9 | 1.5 | |
| P / Cash Flow | · | -6.1 | · | · | · | -17.4 | · | · | · | -6.0 | · | · | -189.9 | · | · | -14.8 | |
| Earnings Yield | -105.5% | -94.9% | · | -113.7% | -15.6% | -26.5% | · | -52.3% | -57.0% | -45.1% | -61.4% | -56.9% | -69.0% | -51.3% | -53.0% | -31.8% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10M | $0 |
| Operating Margin % | -40856.3% | -28899.6% | -15557.8% | -446.8% | · |
| Net Income | $-74M | $-64M | $-50M | $-45M | $-34M |
| Diluted EPS | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 |
| Quick Ratio | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-62M | $-69M | $-37M | $-44M | $-33M |
Institutional owners (13F) 108 filers · $26.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 17 (-22 vs prior Q) | 34 (+26 vs prior Q) | 32 (+4 vs prior Q) | 32 (-4 vs prior Q) | -17.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | $5,078,576 | 8,509,678 | 19.04% | Shares |
| VANGUARD GROUP INC | $3,885,145 | 4,961,871 | 14.57% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $2,273,430 | 3,808,091 | 8.52% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $1,557,975 | 2,610,548 | 5.84% | Shares |
| FMR LLC | $1,474,942 | 2,471,418 | 5.53% | Shares |
| BlackRock, Inc. | $1,090,552 | 1,827,332 | 4.09% | Shares |
| Kalehua Capital Management LLC | $1,067,178 | 1,788,167 | 4.00% | Shares |
| JANE STREET GROUP, LLC | $1,027,270 | 1,721,297 | 3.85% | Shares |
| UBS Group AG | $914,097 | 1,531,151 | 3.43% | Shares |
| MORGAN STANLEY | $801,882 | 1,343,636 | 3.01% | Shares |
| TWO SIGMA INVESTMENTS, LP | $743,104 | 1,245,147 | 2.79% | Shares |
| CITADEL ADVISORS LLC | $741,265 | 1,242,067 | 2.78% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $702,734 | 1,177,020 | 2.63% | Shares |
| TWO SIGMA ADVISERS, LP | $658,861 | 841,350 | 2.47% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $445,833 | 747,039 | 1.67% | Shares |
| MILLENNIUM MANAGEMENT LLC | $391,531 | 656,051 | 1.47% | Shares |
| GOLDMAN SACHS GROUP INC | $382,672 | 641,208 | 1.43% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $343,947 | 576,125 | 1.29% | Shares |
| STATE STREET CORP | $295,387 | 494,951 | 1.11% | Shares |
| H D Vest Advisory Services | $292,382 | 57,669 | 1.10% | Shares |
| MARSHALL WACE, LLP | $220,872 | 368,120 | 0.83% | Shares |
| WOLVERINE TRADING, LLC | $163,096 | 205,100 | 0.61% | Call option |
| CITADEL ADVISORS LLC | $148,603 | 249,000 | 0.56% | Call option |
| XTX Topco Ltd | $135,281 | 226,678 | 0.51% | Shares |
| NORTHERN TRUST CORP | $131,380 | 220,141 | 0.49% | Shares |
| BANK OF AMERICA CORP /DE/ | $123,650 | 207,468 | 0.46% | Shares |
| WOLVERINE TRADING, LLC | $110,453 | 138,900 | 0.41% | Put option |
| JANE STREET GROUP, LLC | $106,588 | 178,600 | 0.40% | Call option |
| RENAISSANCE TECHNOLOGIES LLC | $98,604 | 165,222 | 0.37% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92,880 | 154,800 | 0.35% | Call option |
| JPMORGAN CHASE & CO | $85,337 | 150,666 | 0.32% | Shares |
| GROUP ONE TRADING LLC | $82,882 | 138,878 | 0.31% | Shares |
| Qube Research & Technologies Ltd | $75,791 | 126,996 | 0.28% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $69,900 | 116,500 | 0.26% | Put option |
| DIMENSIONAL FUND ADVISORS LP | $54,114 | 90,861 | 0.20% | Shares |
| WOLVERINE TRADING, LLC | $42,961 | 54,026 | 0.16% | Shares |
| HSBC HOLDINGS PLC | $38,361 | 66,185 | 0.14% | Shares |
| Mariner, LLC | $34,998 | 58,658 | 0.13% | Shares |
| CITADEL ADVISORS LLC | $34,137 | 57,200 | 0.13% | Put option |
| HOHIMER WEALTH MANAGEMENT, LLC | $32,824 | 55,000 | 0.12% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $31,947 | 53,531 | 0.12% | Shares |
| KINGSWOOD WEALTH ADVISORS, LLC | $31,034 | 52,000 | 0.12% | Shares |
| Schonfeld Strategic Advisors LLC | $30,364 | 50,880 | 0.11% | Shares |
| ADAR1 Capital Management, LLC | $30,249 | 50,685 | 0.11% | Shares |
| Alpha Wealth Funds, LLC | $29,890 | 50,000 | 0.11% | Shares |
| Tower Research Capital LLC (TRC) | $29,105 | 48,768 | 0.11% | Shares |
| CWM, LLC | $28,088 | 36,010 | 0.11% | Shares |
| Creative Planning | $24,823 | 41,593 | 0.09% | Shares |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $23,925 | 43,948 | 0.09% | Shares |
| Point72 Asset Management, L.P. | $22,248 | 37,278 | 0.08% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| PAUL SCHIMMEL, PAUL SCHIMMEL PROTOTYPE PSP, PAUL SCHIMMEL, TRUSTEE, FBO PAUL SCHIMMEL ×3 filings | Feb. 14, 2020 | · | Initial filing | · | SEC |
| Polaris Venture Partners V, L.P. (“PVP V”), Polaris Venture Partners Entrepreneurs’ Fund V, L.P. (“PVPE V”), Polaris Venture Partners Founders’ Fund V, L.P. (“PVPFF V”), Polaris Venture Partners Special Founders’ Fund V, L.P. (“PVPSFF V”), Polaris Venture Management Co. V, L.L.C. (“PVM V”), Jonathan A. Flint, Terrance G. McGuire, Amir Nashat ×2 filings | July 17, 2019 | · | Initial filing | · | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×3 filings | Feb. 12, 2019 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 34 insiders · 18 officers · 12 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Sanjay Shukla | President and CEO | Feb. 3, 2026 M | 153,553 | 0 | 1 | $-3,670 |
| Brandon Yaras | Chief Financial Officer | Oct. 1, 2026 A | · | 0 | 0 | $0 |
| Jill Marie Broadfoot | Chief Financial Officer | Feb. 3, 2026 M | 37,296 | 0 | 1 | $-1,527 |
| Stan Blackburn | Acting Chief Financial Officer | Jan. 27, 2016 A | · | 0 | 0 | $0 |
| Frederic Chereau | President & COO | May 6, 2015 A | · | 0 | 0 | $0 |
| Nancy Krueger | General Counsel | Feb. 3, 2026 M | 33,124 | 0 | 1 | $-1,096 |
| Ashraf Amanullah | Senior Vice President, Biologics Development and Manufacturing | May 31, 2018 M | 26,264 | 0 | 0 | $0 |
| John T Blake | Senior Vice President, Finance | Feb. 7, 2018 M | 1,932 | 0 | 0 | $0 |
| David John King | Chief Scientific Officer | Feb. 6, 2018 A | · | 0 | 0 | $0 |
| Sanuj K. Ravindran | Chief Business Officer | Feb. 7, 2017 A | · | 0 | 0 | $0 |
| Andrew Cubitt | VP, Product Protection | Sept. 13, 2016 A | · | 0 | 0 | $0 |
| Kelly Blackburn | VP, Clinical Affairs | March 28, 2016 A | · | 0 | 0 | $0 |
| Melissa A. Ashlock | SVP, Translational Medicine and Therapeutics | Jan. 27, 2016 A | · | 0 | 0 | $0 |
| John C. Mckew | VP, Research | Jan. 27, 2016 A | · | 0 | 0 | $0 |
| Holly D. Chrzanowski | VP, Enterprise Talent & Organization | Jan. 27, 2016 A | · | 0 | 0 | $0 |
| Marcy Graham | VP, Investor Relations and Corporate Communications | Jan. 4, 2016 A | · | 0 | 0 | $0 |
| Fred Ramsdell | VP, Immunology | Oct. 1, 2015 A | · | 0 | 0 | $0 |
| David M. Weiner | Chief Medical Officer | May 6, 2015 A | · | 0 | 0 | $0 |
| SCHIMMEL PAUL | Director | May 27, 2026 P | 779,143 | 3 | 0 | $962,720 |
| Svetlana Lucas | Director | May 11, 2026 A | 6,000 | 0 | 0 | $0 |
| Jane A Gross | Director | May 11, 2026 A | 9,750 | 0 | 0 | $0 |
| Eric Benevich | Director | May 11, 2026 A | · | 0 | 0 | $0 |
| Sara Zaknoen | Director | May 11, 2026 A | 6,000 | 0 | 0 | $0 |
| John K Clarke | Director | May 22, 2024 A | 19,797 | 0 | 0 | $0 |
| Jeffrey S. Hatfield | Director | May 6, 2020 A | · | 0 | 0 | $0 |
| John Mendlein | Director | May 8, 2019 A | 615,382 | 0 | 0 | $0 |
| BLAIR JAMES C | Director | May 8, 2019 A | · | 0 | 0 | $0 |
| Amir Nashat | Director | May 15, 2018 A | 17,638 | 0 | 0 | $0 |
| Kathryn E Falberg | Director | May 24, 2016 A | · | 0 | 0 | $0 |
| EcoR1 Capital Fund Qualified, L.P. | 10% owner | May 16, 2018 S | 0 | 0 | 0 | $0 |
| Timothy Coughlin | · | May 11, 2026 A | 56,000 | 0 | 0 | $0 |
| Mark Alan Goldberg | · | May 9, 2017 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | · | May 9, 2017 A | 1,866,126 | 0 | 0 | $0 |
| Grove Matsuoka | · | Feb. 7, 2017 A | 12,412 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
ATYR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
7 analysts · 2026-10-01Mean target $2.86 +894.8%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.